Omada Health (NASDAQ:OMDA) CFO Sells $325,433.50 in Stock

Omada Health, Inc. (NASDAQ:OMDA) CFO Steven Cook sold 17,950 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $18.13, for a total transaction of $325,433.50. Following the completion of the transaction, the chief financial officer owned 169,259 shares in the company, valued at $3,068,665.67. This represents a 9.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Omada Health Stock Performance

Omada Health stock opened at $20.89 on Friday. The company has a 50 day moving average price of $16.51 and a 200-day moving average price of $14.85. Omada Health, Inc. has a fifty-two week low of $10.28 and a fifty-two week high of $26.92. The company has a market capitalization of $1.24 billion and a PE ratio of -77.37.

Omada Health (NASDAQ:OMDA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03. The firm had revenue of $78.05 million during the quarter. Omada Health had a negative return on equity of 1.82% and a negative net margin of 2.22%. On average, analysts forecast that Omada Health, Inc. will post -0.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

OMDA has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Omada Health in a research report on Thursday, June 4th. Citigroup reaffirmed an “outperform” rating on shares of Omada Health in a research note on Friday, May 8th. Evercore reiterated an “outperform” rating and set a $20.00 target price on shares of Omada Health in a report on Friday, May 8th. Canaccord Genuity Group set a $24.00 target price on shares of Omada Health in a research report on Friday, May 8th. Finally, Citizens Jmp boosted their price target on shares of Omada Health from $18.00 to $21.00 and gave the company a “market outperform” rating in a report on Friday, May 8th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.91.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in OMDA. Geode Capital Management LLC purchased a new stake in shares of Omada Health during the 2nd quarter worth $637,000. Walleye Capital LLC purchased a new position in Omada Health in the second quarter valued at about $458,000. Ilex Capital Partners UK LLP purchased a new position in Omada Health in the second quarter valued at about $201,000. Soros Fund Management LLC bought a new position in Omada Health in the second quarter worth about $640,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of Omada Health during the second quarter valued at about $32,000.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.